News

Avella Newsroom

January 1, 1970|
Simple Technology Extends Patient’s Time on Therapy with Specialty Medications for up to 3.5 Months
July 18, 2018| CATEGORIES: Adherence , Press Release

CareSpeak’s automated patient engagement platform extended days on therapy for Avella patients with cancer by 73 days and with inflammatory disease by 102 days.

PHOENIX, AZAvella Specialty Pharmacy has just published new data showing that automated patient engagement, in combination with patient monitoring and trigger-based pharmacist interventions, have a significant impact on patient adherence and persistence. 

Avella’s Use of AdhereTech Improves Adherence and Generates One to Two Additional Fills Per Patient Per Year, Across Multiple Specialty Medications and Diseases
July 10, 2018| CATEGORIES: Adherence , Press Release

The specialty pharmacy uses AdhereTech smart pill bottles for multiple specialty medications from various manufacturers, with consistent improvements in adherence, duration, refills, and the patient experience.

Phoenix, AZ – Avella Specialty Pharmacy and AdhereTech are proud to share the results that their successful partnership continues to have for patients. Avella currently uses the AdhereTech program for five specialty medications, in programs with four different pharmaceutical manufacturers. Averaged across all patients and programs from 2015 through today, AdhereTech has improved duration on therapy by 26%, fill rates by 9%, and dose-level adherence by 15%. On average, the AdhereTech program generates 1 to 2 additional fills of specialty medications, per patient per year.

Avella Selected by Array BioPharma Inc. to Distribute BRAFTOVI (encorafenib) and MEKTOVI (binimetinib)
June 27, 2018| CATEGORIES: Oncology , Cancer , Press Release

The specialty pharmacy will give patients access to this important new FDA-approved combination therapy for patients with advanced BRAF melanoma.

Phoenix, AZ -- Avella has announced that it will distribute BRAFTOVI™ (encorafenib) and MEKTOVI® (binimetinib), a combination therapy recently FDA approved for patients for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. 

Avella Selected by Otsuka to distribute JYNARQUE
April 27, 2018| CATEGORIES: Press Release

The specialty pharmacy will give patients access to this new therapy for polycystic kidney disease, the only FDA-approved drug available in the US to treat this condition.

Phoenix, AZ -- Avella announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE™ (tolvaptan), the very first FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD). Avella is one of just three pharmacies providing access to the medication.

Avella Releases New Report on Anticipated Specialty Drug Approvals
April 27, 2018| CATEGORIES: Press Release , limited distribution drugs , Specialty Pharmacy

The leading specialty pharmacy has compiled insights about the specialty drug pipeline along with an analysis of the network distribution strategies for these medications.

Phoenix, AZ -- Avella has just announced the release of a 16-page report detailing the specialty drug pipeline, including all of the latest medications expected to receive FDA approval within the coming months. The 2018 Q2 Specialty Medication Pipeline Report provides at-a-glance information about all of these therapies including indications, approval status, anticipated costs, clinical considerations and therapeutic alternatives, among other key data points. It also provides helpful explanations of the various designations and approval processes undertaken by the FDA for specific types of medication such as orphan drugs and breakthrough therapies.

Avella to Improve Access to Naloxone, an Opioid Overdose-Reversing Medication, Through an Innovative New Program
April 24, 2018| CATEGORIES: Addiction Management , Pain Management , Press Release

The program’s launch will help further the Surgeon General’s efforts to encourage Americans
to carry this drug and help save lives.

Phoenix, AZ -- Avella has announced it will distribute naloxone, a powerful therapy used to treat opioid overdoses, as part of an innovative new program designed to improve access to the drug. The program allows individuals and family members in certain states to simply contact the pharmacy and order the drug by phone, with no physician prescription needed. In these circumstances, one of Avella’s pharmacists will actually supply the prescription if they determine that EVZIO® (naloxone HCl injection) or another naloxone therapy is appropriate. 

The Leukemia & Lymphoma Society (LLS) Names Avella Executive Hamilton Baiden as the Corporate Walk Chair for Greater Phoenix Light The Night
March 29, 2018| CATEGORIES: Press Release , LLS , Avella , Oncology

Phoenix, AZ – The Arizona Chapter of The Leukemia & Lymphoma Society (LLS) announced today that Avella Specialty Pharmacy Executive Vice President Hamilton Baiden will serve as the Corporate Walk Chair of the 2018 Greater Phoenix Light The Night.

Avella Is Now the Third Largest Privately-Held Company in the State According to the Arizona Corporate Excellence (ACE) Awards.
November 3, 2017| CATEGORIES: Press Release , Avella , ACE Awards

Phoenix, AZ -- Avella Specialty Pharmacy announced that it has been named the third largest privately-held company in the state by the Phoenix Business Journal through its Arizona Corporate Excellence (ACE) Awards. Avella moved up from its rank as the fourth largest in 2016 and was also recognized as the sixth fastest-growing company in Arizona this year.

Avella Selected by AstraZeneca to Distribute CALQUENCE® (acalabrutinib)
October 31, 2017| CATEGORIES: Press Release , Oncology

The specialty pharmacy will provide access to this FDA-approved, second-generation treatment for mantle cell lymphoma

Avella Launches NurseConnect Program to Engage and Support Patients
October 18, 2017| CATEGORIES: Avella , Press Release

New program combines advanced technology, nurse outreach and a flexible support model to advance each patients treatment journey.

Phoenix AZ -- Avella has announced the introduction of a new patient support program, NurseConnect, designed to engage and educate individuals taking powerful specialty drugs to manage their health conditions. Avella’s highly-trained nurses deliver outreach through a variety of modalities, including video, screen sharing, text and traditional phone calls. This flexible model allows the specialty pharmacy to personalize each engagement approach based on the patient’s needs and preferences.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe
Featured Video
Photo of Brian Halligan
Path of a Specialty Prescription
The path of a specialty prescription is complex. This video details each step of the path and the unique offerings of Avella.
Media Contact

Sarah McLeod
800-516-2881  x103
smcleod@activate-health.com

Avella is available to coordinate subject matter expert interviews on a variety of topics including.

  • Specialty pharmacy/pharmacist role
  • Medication adherence and technology
  • Specialty pharmacy pricing considerations

Please contact Sarah McLeod for more information about Avella Specialty Pharmacy.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe